WO2014135896A3 - Beta-2-adrenergic receptor agonist for improving sin scar colour matching - Google Patents

Beta-2-adrenergic receptor agonist for improving sin scar colour matching Download PDF

Info

Publication number
WO2014135896A3
WO2014135896A3 PCT/GB2014/050686 GB2014050686W WO2014135896A3 WO 2014135896 A3 WO2014135896 A3 WO 2014135896A3 GB 2014050686 W GB2014050686 W GB 2014050686W WO 2014135896 A3 WO2014135896 A3 WO 2014135896A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
hyperpigmentation
scar
risk
colour matching
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2014/050686
Other languages
French (fr)
Other versions
WO2014135896A2 (en
Inventor
Christine Elaine Pullar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Original Assignee
University of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leicester filed Critical University of Leicester
Priority to US14/772,895 priority Critical patent/US9943471B2/en
Priority to JP2015560779A priority patent/JP6496670B2/en
Priority to PCT/GB2014/050686 priority patent/WO2014135896A2/en
Priority to DK14716626.8T priority patent/DK2964206T3/en
Priority to KR1020157024363A priority patent/KR20150128695A/en
Priority to ES14716626T priority patent/ES2748609T3/en
Priority to BR112015021668-4A priority patent/BR112015021668B1/en
Priority to EP14716626.8A priority patent/EP2964206B1/en
Publication of WO2014135896A2 publication Critical patent/WO2014135896A2/en
Publication of WO2014135896A3 publication Critical patent/WO2014135896A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)

Abstract

A method for improving skin scar colour matching, for example reducing scar hyperpigmentation, the method comprising administering a therapeutically effective amount of an agent, which positively modulates β2-adrenergic receptor conformation, or receptor activity, or activation thereof, to a subject in need thereof. The subject typically is in need of improving skin scar colour matching, for example reducing scar hyperpigmentation, because the subject has or is at risk of hyperpigmentation. The subject typically is selected as being at risk of hyperpigmentation on the basis of one or more of the following factors: · the subject has previously developed hyperpigmentation of a scar • the subject tans readily on exposure to sunshine or ultraviolet (UV) radiation, rather than burning • the subject has a non-Caucasian racial origin • the subject's skin colour (for example in an area that is not tanned) is considered to be darker than that typical of a naturally fair-haired Caucasian person. The subject may be selected as being at risk of hyperpigmentation because they are at least predominantly of Chinese, black African, Asian or Southern European racial origin, and/or if their skin type can be assessed under the Fitzpatrick Scale as Type III, IV, V or VI.
PCT/GB2014/050686 2013-03-08 2014-03-07 Methods Ceased WO2014135896A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/772,895 US9943471B2 (en) 2013-03-08 2014-03-07 Beta-2-adrenergic receptor agonist for improving skin scar colour matching
JP2015560779A JP6496670B2 (en) 2013-03-08 2014-03-07 Beta-2-adrenergic receptor agonists for improving color matching of skin scars
PCT/GB2014/050686 WO2014135896A2 (en) 2013-03-08 2014-03-07 Methods
DK14716626.8T DK2964206T3 (en) 2013-03-08 2014-03-07 BETA-2-ADRENERG RECEPTOR AGONIST FOR IMPROVING SKIN CUSTOMIZATION
KR1020157024363A KR20150128695A (en) 2013-03-08 2014-03-07 Beta-2-adrenergic receptor agonist for improving skin scar colour matching
ES14716626T ES2748609T3 (en) 2013-03-08 2014-03-07 Beta-2-adrenergic receptor agonist to match the color of skin scars
BR112015021668-4A BR112015021668B1 (en) 2013-03-08 2014-03-07 SS2-ADRENERGIC RECEPTOR AGONIST TO IMPROVE SCAR SKIN COLOR MATCHING
EP14716626.8A EP2964206B1 (en) 2013-03-08 2014-03-07 Beta-2-adrenergic receptor agonist for improving skin scar colour matching

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1304234.6A GB2513297A (en) 2013-03-08 2013-03-08 Methods
GB1304234.6 2013-03-08
PCT/GB2014/050686 WO2014135896A2 (en) 2013-03-08 2014-03-07 Methods

Publications (2)

Publication Number Publication Date
WO2014135896A2 WO2014135896A2 (en) 2014-09-12
WO2014135896A3 true WO2014135896A3 (en) 2014-11-13

Family

ID=48189617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/050686 Ceased WO2014135896A2 (en) 2013-03-08 2014-03-07 Methods

Country Status (9)

Country Link
US (1) US9943471B2 (en)
EP (1) EP2964206B1 (en)
JP (1) JP6496670B2 (en)
KR (1) KR20150128695A (en)
BR (1) BR112015021668B1 (en)
DK (1) DK2964206T3 (en)
ES (1) ES2748609T3 (en)
GB (1) GB2513297A (en)
WO (1) WO2014135896A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606177B (en) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 Medicinal application of left-handed (R) salbutamol formulation in treatment skin and mucous membrane trauma ulcer
CN110841208B (en) * 2018-08-21 2023-05-02 魏琳 A beauty instrument for whitening and removing freckles
JP2023530679A (en) * 2020-06-11 2023-07-19 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク Methods and compositions for preventing and treating myopia using fenoterol hydrobromide, beta-2 adrenergic receptor agonists, and derivatives thereof
CN120053410A (en) * 2025-01-16 2025-05-30 青岛大学附属医院 Application of propranolol in preparation of functional drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118541A1 (en) * 2008-03-27 2009-10-01 The University Of Leicester Modulation of fibroblast activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2740040B1 (en) 1995-10-23 1997-12-05 Oreal USE OF AT LEAST ONE BETA-ADRENERGIC AGONIST AS A SUBSTANCE P ANTAGONIST
NZ522882A (en) 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
EP1496917B1 (en) 2002-04-19 2005-12-07 Astion Development A/S Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
WO2006027579A2 (en) 2004-09-07 2006-03-16 Sosei R & D Ltd. The treatment of inflammatory disorders and pain
WO2006108176A2 (en) * 2005-04-08 2006-10-12 The Regents Of The University Of California Wound healing composition
CN101203214B (en) * 2005-04-13 2012-11-21 艾升制药公司 Beta2-adrenoceptor agonists for the treatment of connective tissue diseases of the skin
EP1764081A1 (en) 2005-08-29 2007-03-21 Johnson & Johnson Consumer France SAS Sunscreen composition comprising a dibenzoylmethane, an aminohydroxybenzophenone, a triazine and a triazole as UV filters
JP2009537570A (en) 2006-05-18 2009-10-29 ティカ レーケメデル アーベー Unit dose formulation with inhalable solution of albuterol
MX2010002999A (en) 2007-09-18 2010-06-02 Schering Plough Healthcare Sunscreen compositions with low eye-sting and high spf.
GB0724204D0 (en) * 2007-12-12 2008-01-23 Renovo Ltd Methods for inhibition of scarring
WO2012170695A2 (en) 2011-06-08 2012-12-13 Mary Kay Inc. Sunscreen formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118541A1 (en) * 2008-03-27 2009-10-01 The University Of Leicester Modulation of fibroblast activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. E. PULLAR: "Beta-2-Adrenergic receptor activation delays wound healing", THE FASEB JOURNAL, vol. 20, no. 1, 1 January 2006 (2006-01-01), pages 76 - 86, XP055118116, ISSN: 0892-6638, DOI: 10.1096/fj.05-4188com *
J. M. GILLBRO ET AL: "The melanogenesis and mechanisms of skin-lightening agents - existing and new approaches", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, 1 January 2011 (2011-01-01), pages no - no, XP055000016, ISSN: 0142-5463, DOI: 10.1111/j.1468-2494.2010.00616.x *
JOHANNA M GILLBRO ET AL: "Autocrine Catecholamine Biosynthesis and the beta-2-Adrenoceptor Signal Promote Pigmentation in Human Epidermal Melanocytes", 2 August 2004 (2004-08-02), pages 346 - 353, XP055118161, Retrieved from the Internet <URL:http://www.nature.com/jid/journal/v123/n2/pdf/5602440a.pdf> [retrieved on 20140515] *

Also Published As

Publication number Publication date
KR20150128695A (en) 2015-11-18
JP2016510061A (en) 2016-04-04
GB2513297A (en) 2014-10-29
BR112015021668A2 (en) 2017-07-18
EP2964206B1 (en) 2019-07-17
DK2964206T3 (en) 2019-10-07
US9943471B2 (en) 2018-04-17
WO2014135896A2 (en) 2014-09-12
EP2964206A2 (en) 2016-01-13
BR112015021668B1 (en) 2022-03-08
JP6496670B2 (en) 2019-04-03
ES2748609T3 (en) 2020-03-17
GB201304234D0 (en) 2013-04-24
US20160008247A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
BR112013004051A2 (en) Enhanced recombinant human follicle hormone and stimulant.
WO2014135896A3 (en) Beta-2-adrenergic receptor agonist for improving sin scar colour matching
WO2011109224A8 (en) Gene sets for detection ultraviolet a exposure and methods of use thereof
WO2011106792A3 (en) Analytic methods of tissue evaluation
WO2010017556A8 (en) Method and apparatus for fractional deformation and treatment of cutaneous and subcutaneous tissue
WO2010078985A3 (en) Cosmetic method for controlling browning of the skin induced by uv radiation; compositions
WO2016201450A3 (en) Cancer treatment and diagnosis
SG173683A1 (en) Methods and systems for diagnosis and treatment of a defined condition, and methods for operating such systems
BR112012012131A2 (en) use of alpha-2 adrenergic receptor agonists to treat or prevent psoriasis
EA201891507A1 (en) ACID ALPHA-GLUCOSIDASE OF STRENGTHENING ACTION FOR THE TREATMENT OF POMPE DISEASE
MY209907A (en) Microrna-based therapy targeted against lcp-1 positive cancers
WO2015089338A3 (en) Glucocorticoid inhibitors for treatment of prostate cancer
WO2011019815A3 (en) Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
NZ731850A (en) System and method for preventing alopecia
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MX2014000537A (en) Method for assessing condition of skin and/or scalp.
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
MX366410B (en) Compositions and methods for treating and repairing tendons.
EP3991716A4 (en) Hyaluronic acid skin protection composition, and preparation method therefor and application thereof
WO2011119794A3 (en) Hair removal method and hair removal kit
Amat et al. Newton-type methods on Riemannian manifolds under Kantorovich-type conditions
JP2016510061A5 (en)
AU2014352875A8 (en) Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
WO2009086189A3 (en) Use of activating transcription factor-2 (atf2) for detecting skin cancer
WO2009011899A3 (en) Methods for identifying treatments that treat and/or prevent uv irradiation induced photoaging

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14716626

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14772895

Country of ref document: US

Ref document number: 2014716626

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157024363

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2015560779

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015021668

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015021668

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150904